The success rate of long-acting interferon in treating hepatitis B is generally not high, but the use of interferon can improve the chances of hepatitis B cure. Long-acting interferon is a broad-spectrum antiviral drug, which can not directly kill or inhibit the virus, but can prompt cells to produce antiviral proteins through the action of antibodies on the cell surface, so as to achieve the purpose of inhibiting the replication of the hepatitis B virus, but it often fails to achieve the purpose of cure. Long-acting interferon also has a certain immunomodulatory effect. Clinical treatment of hepatitis B in the process, a large proportion of patients in the body of the hepatitis B virus can be effectively controlled, especially the hepatitis B surface antigen titer is lower in young patients can achieve better results, but not all patients applying long-acting interferon is a good effect, there are certain individual differences, in general, after interferon treatment of hepatitis B is still not a high rate of complete cure. Common adverse effects of long-acting interferon include palpitations (rapid heartbeat, often accompanied by panic), anemia, eye pain, dry eyes and eye inflammation, etc. It is contraindicated in pregnancy and lactation, and contraindicated in those who are allergic to long-acting interferon. The use of long-acting interferon is also associated with greater risk, and it is recommended that patients need to use it under the guidance of a specialist, and should not use it without authorization.